(3R,4S,5S,6R)-5-methoxy-4-[(3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]oct-6-yl (chloroacetyl)carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3R,4S,5S,6R)-5-methoxy-4-[(3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]oct-6-yl (chloroacetyl)carbamate
• 英文别名: [(3R,4S,5S,6R)-5-methoxy-4-[(3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl]-1-oxaspiro[2.5]octan-6-yl] N-(2-chloroacetyl)carbamate
• 化学式: C₁₉H₂₈ClNO₆
• 分子量: 401.9
• InChiKey: MSHZHSPISPJWHW-DWYAXKQASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  89.7
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES
  申请人：AKULLIAN Laura C.

  公开号：US20090148396A1

  公开（公告）日：2009-06-11

  Fumagillin analog polymer conjugates, methods of making fumagillin analog polymer conjugates, compositions comprising a polymer conjugate of a fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a polymer conjugate of a fumagillin analog, are described. Also described are novel fumagillin analogs, methods of making fumagillin analogs, compositions comprising at least one fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a fumagillin analog.
• US8399512B2
  申请人：——

  公开号：US8399512B2

  公开（公告）日：2013-03-19
• [EN] BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES<br/>[FR] CONJUGUÉS D'ANALOGUES DE FUMAGILLINE BIOCOMPATIBLES ET BIODÉGRADABLES
  申请人：MERSANA THERAPEUTICS INC

  公开号：WO2009073445A2

  公开（公告）日：2009-06-11

  Fumagillin analog polymer conjugates, methods of making fumagillin analog polymer conjugates, compositions comprising a polymer conjugate of a fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a polymer conjugate of a fumagillin analog, are described. Also described are novel fumagillin analogs, methods of making fumagillin analogs, compositions comprising at least one fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a fumagillin analog.